In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...

Bayer said on Tuesday it was preparing market launches this year of two new drugs that could each have annual peak sales of ...

BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...

Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...

Bayonetta creator Hideki Kamiya has defended Assassin’s Creed Shadows believing the game has received a lot of hate from a ...

Ex-Platinum Games employee Hideki Kamiya has seemingly joined the debate surrounding Assassin's Creed Shadows.

So, in summary, Japanese reviewers haven't quite put Assassin's Creed Shadows on the same pedestal as Ghost of Tsushima — ...

Alexion, AstraZeneca Rare Disease will be responsible for all commercial activity for Beyonttra in Japan. “There is significant need for new treatment options for ATTR-CM, a progressive ...

In a statement, the German maker of drugs and agricultural supplies said it would bring Beyonttra, also known as acoramidis, to market to treat a condition that results in heart failure.

JAMA Cardiol. 2024 Dec 4:e244102. Beyonttra is an orally administered near-complete (≥90%) stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin ...